Should guidelines be revised for add-on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care

Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care

Session: Wider aspects of managing respiratory disease in primary care
Session type: E-Communication Session
Number: 233

Disease area: Airway diseases



Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Sims, D. Freeman, L. Kemp, S. Musgrave, L. Juniper, R. Gilbert, J. Ayres, A. Blyth, I. Harvey, E. Wilson, M. Mugford, S. Wolfe, L. Shepstone, J. Murdoch, D. Price (Norwich, Aberdeen, Hamilton, United Kingdom). Should guidelines be revised for add-on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care. Eur Respir J 2008; 32: Suppl. 52, 233

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

• The Relationship Between Functional Status and Fatigue After COVID-19 Infection
• Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
• Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency